The underlying cause of thyroid ophthalmopathy and the development of the novel treatment

2014 Fiscal Year Final Research Report

• Project/Area Number: 23592598
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Ophthalmology
• Research Institution: Hyogo Medical University
• Principal Investigator: MIMURA Osamu 兵庫医科大学, 医学部, 教授 (60157584)
• Co-Investigator(Kenkyū-buntansha): ISHIKAWA Hiroto 兵庫医科大学, 医学部, 講師 (10434945) ; KIMURA Akiko 兵庫医科大学, 医学部, 准教授 (10368524) ; TAKATA Masashi 兵庫医科大学, 医学部, 助教 (60617984) ; KIMURA Naoki 兵庫医科大学, 医学部, 講師 (10368523)
• Project Period (FY): 2011-04-28 – 2015-03-31
• Keywords: 甲状腺眼症 / 生物製剤 / インフリキシマブ

Outline of Final Research Achievements

In the present study, we found the elevation of macrophage inflammatory protein of the extraocular muscle (MIP-1β、STNFRI etc) in patients with thyroid ophthalmopathy. Then, we started a clinical trial named " Investigation into the therapeutic effects of infliximab in patients with thyroid ophthalmopathy". The objectives were severe patients with thyroid ophthalmopathy who were uncontrollable by the conventional treatment such as steroids. After the infliximab treatment, they did not present any adverse event and had a subjective improvement. However, they did not have an objective improvement, suggesting that there was a poor evidence about the therapeutic effects of infliximab in patients with thyroid ophthalmopathy.

Free Research Field

神経眼科